Copyright
©The Author(s) 2022.
World J Clin Cases. Nov 16, 2022; 10(32): 11804-11811
Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11804
Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11804
Table 2 Comparison of T-cell immunoglobulin mucin molecule-3, transforming growth factor β, and chemokine 12 expression between patients with effective and ineffective after diffuse large B-cell lymphoma treatment, n (%)
| Groups | Tim-3 positive | TGF-β positive | CXCL12 positive |
| Effective (n = 51) | 47 (92.16) | 39 (76.47) | 48 (94.12) |
| Ineffective (n = 46) | 26 (56.52) | 12 (26.09) | 34 (73.91) |
| χ2 value | 16.4939 | 24.6236 | 7.553 |
| P value | 0.000 | 0.000 | 0.006 |
- Citation: Wu H, Sun HC, Ouyang GF. T-cell immunoglobulin mucin molecule-3, transformation growth factor β, and chemokine-12 and the prognostic status of diffuse large B-cell lymphoma. World J Clin Cases 2022; 10(32): 11804-11811
- URL: https://www.wjgnet.com/2307-8960/full/v10/i32/11804.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i32.11804